EUCTR2014-002632-14-ES进行中（未招募）1 期
A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART - ODYSSEY (Once daily DTG-based ART in young people vs standard therapy)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Children <18 years with confirmed HIV-1 infection and DTG dose known for child?s age/weight-band*
- •? Parents/carers and children, where applicable, give informed written consent
- •? Girls who have reached menses must have a negative pregnancy test at screening and randomisation and be willing to adhere to effective methods of contraception if sexually active
- •? Children with co-infections who need to start ART can be enrolled into ODYSSEY according to local/national guidelines
- •? Parents/carers and children, where applicable, willing to adhere to a minimum of 96 weeks' follow-up
- •*Recruitment will start from children aged ?6 and<18 years for whom dosing information and formulations are currently available. Additional formulations for younger children will become available during the trial and dosing information will be updated.
- •Additional criteria for ODYSSEY A:
- •? Planning to start first-line ART
- •Additional criteria for ODYSSEY B:
- •? Planning to start second-line ART defined as switch of at least 2 ART drugs due to treatment failure
- •? Treated with only one previous ART regimen. Single drug substitutions for toxicity are allowed.
- •? At least one NRTI with predicted preserved activity available for a background regimen
- •? In settings where resistance tests are routinely available, at least one new active NRTI from tenofovir, abacavir or zidovudine should have preserved activity based on cumulative results of resistance tests within 3 months
- •? In settings where resistance tests are not routinely available, children who are due to switch according to national guidelines should have at least one new NRTI available from tenofovir, abacavir or zidovudine
- •? Viral load >1000 c/ml at screening visit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 700
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •? History or presence of known allergy or some other contraindication to the study drugs or their components
- •? Alanine aminotransferase (ALT) ?5 times the upper limit of normal (ULN), OR ALT ?3xULN and bilirubin ?2xULN
- •? Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- •? Anticipated need for Hepatitis C virus (HCV) therapy during the study
- •? Pregnancy or breastfeeding
- •? Evidence of lack of susceptibility to integrase inhibitors or more than a 2-week exposure to antiretrovirals of this class
- •? Contraindications to proposed available NRTI backbone.
研究者
相似试验
进行中（未招募）
1 期
A randomised trial of dolutegravir (DTG)-based antiretroviral treatment vs standard of care (SOC) in children with HIV infection starting first treatment or switching to second-line antiretrovirals.Paediatric HIV infectionMedDRA version: 20.0Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-002632-14-FRFondazione PENTA ONLUS700
进行中（未招募）
1 期
A randomised trial of dolutegravir (DTG)-based antiretroviral treatment vs standard of care (SOC) in children with HIV infection starting first treatment or switching to second-line antiretrovirals.Paediatric HIV infectionMedDRA version: 20.0Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-002632-14-PTFondazione PENTA ONLUS700
进行中（未招募）
1 期
A randomised trial of dolutegravir (DTG)-based antiretroviral treatment vs standard of care (SOC) in children with HIV infection starting first treatment or switching to second-line antiretroviralsPaediatric HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-002632-14-DEPENTA Foundation792
招募中
2 期
Evaluation of the effect of an antiretroviral drug in patients infected with HTLV-1.Human T-lymphotropic virus 1B04RBR-5x7ccxpFundação Bahiana de Infectologia - FBA
尚未招募
Unknown
Benefits and safety of major medicines in HIV patients.CTRI/2024/04/065522Institute of Medical Sciences, Banaras Hindu University